Novartis to give prior notice for domestic introduction of Entresto

‘Entresto,’ a Novartis’s new cardiac insufficiency drug, will be introduced in Korea.

According to the industry concerned on the 16^th, Novartis has applied for the domestic approval of Entresto, a valsartan+sacubitril cardiac insufficiency treatment, which has lately been called as ‘LCZ696.’

While approved from the US FDA last July, the drug was begun to make domestic approval procedure last ...